Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
50,973,571
-
Total 13F shares
-
2,167,593
-
Share change
-
+341,323
-
Total reported value
-
$7,087,336
-
Price per share
-
$3.28
-
Number of holders
-
11
-
Value change
-
+$1,118,949
-
Number of buys
-
8
-
Number of sells
-
4
Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q1 2025
As of 31 Mar 2025,
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,167,593 shares.
The largest 10 holders included
SCOTIA CAPITAL INC., ROYAL BANK OF CANADA, TD Waterhouse Canada Inc., BANK OF MONTREAL /CAN/, UBS Group AG, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, RAYMOND JAMES FINANCIAL INC, JPMORGAN CHASE & CO, and BANK OF AMERICA CORP /DE/.
This page lists
11
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.